A citation-based method for searching scientific literature

Richard G Langley, Steven R Feldman, Chenglong Han, Brad Schenkel, Philippe Szapary, Ming-Chun Hsu, Jean-Paul Ortonne, Kenneth B Gordon, Alexa B Kimball. J Am Acad Dermatol 2010
Times Cited: 118







List of co-cited articles
1474 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
Stephen Tyring, Alice Gottlieb, Kim Papp, Ken Gordon, Craig Leonardi, Andrea Wang, Deepa Lalla, Michael Woolley, Angelika Jahreis, Ralph Zitnik,[...]. Lancet 2006
726
53

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
Alan Menter, Matthias Augustin, James Signorovitch, Andrew P Yu, Eric Q Wu, Shiraz R Gupta, Yanjun Bao, Parvez Mulani. J Am Acad Dermatol 2010
94
46

A meta-analysis of cytokines in major depression.
Yekta Dowlati, Nathan Herrmann, Walter Swardfager, Helena Liu, Lauren Sham, Elyse K Reim, Krista L Lanctôt. Biol Psychiatry 2010
29

The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.
Shanu Kohli Kurd, Andrea B Troxel, Paul Crits-Christoph, Joel M Gelfand. Arch Dermatol 2010
399
28

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Kim A Papp, Richard G Langley, Mark Lebwohl, Gerald G Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li,[...]. Lancet 2008
27

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
Charles L Raison, Robin E Rutherford, Bobbi J Woolwine, Chen Shuo, Pamela Schettler, Daniel F Drake, Ebrahim Haroon, Andrew H Miller. JAMA Psychiatry 2013
859
27

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Craig L Leonardi, Alexa B Kimball, Kim A Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T Dooley, Kenneth B Gordon. Lancet 2008
26

From inflammation to sickness and depression: when the immune system subjugates the brain.
Robert Dantzer, Jason C O'Connor, Gregory G Freund, Rodney W Johnson, Keith W Kelley. Nat Rev Neurosci 2008
21

Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials.
Ole Köhler, Michael E Benros, Merete Nordentoft, Michael E Farkouh, Rupa L Iyengar, Ole Mors, Jesper Krogh. JAMA Psychiatry 2014
441
21

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
M Lebwohl, K Papp, C Han, B Schenkel, N Yeilding, Y Wang, G G Krueger. Br J Dermatol 2010
76
25

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Alan Menter, Stephen K Tyring, Kenneth Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Bruce E Strober, Martin Kaul, Yihua Gu, Martin Okun,[...]. J Am Acad Dermatol 2008
597
19

The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis.
Emmilia A Dowlatshahi, Marlies Wakkee, Lidia R Arends, Tamar Nijsten. J Invest Dermatol 2014
175
19

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Kristian Reich, Frank O Nestle, Kim Papp, Jean-Paul Ortonne, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Christopher E M Griffiths. Lancet 2005
776
18

Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
M Bryant Howren, Donald M Lamkin, Jerry Suls. Psychosom Med 2009
18

The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries.
Florence J Dalgard, Uwe Gieler, Lucia Tomas-Aragones, Lars Lien, Francoise Poot, Gregor B E Jemec, Laurent Misery, Csanad Szabo, Dennis Linder, Francesca Sampogna,[...]. J Invest Dermatol 2015
336
18

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Christopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, Bei Zhou, Shu Li,[...]. N Engl J Med 2010
597
17

Psoriasis causes as much disability as other major medical diseases.
S R Rapp, S R Feldman, M L Exum, A B Fleischer, D M Reboussin. J Am Acad Dermatol 1999
983
16

Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
S R Feldman, A B Gottlieb, M Bala, Y Wu, D Eisenberg, C Guzzo, S Li, L T Dooley, A Menter. Br J Dermatol 2008
61
26

Etanercept as monotherapy in patients with psoriasis.
Craig L Leonardi, Jerold L Powers, Robert T Matheson, Bernard S Goffe, Ralph Zitnik, Andrea Wang, Alice B Gottlieb. N Engl J Med 2003
870
16

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
16

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
K Reich, F O Nestle, K Papp, J-P Ortonne, Y Wu, M Bala, R Evans, C Guzzo, S Li, L T Dooley,[...]. Br J Dermatol 2006
102
15

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
Kenneth B Gordon, Richard G Langley, Craig Leonardi, Darryl Toth, M Alan Menter, Sewon Kang, Michael Heffernan, Bruce Miller, Regina Hamlin, Liberata Lim,[...]. J Am Acad Dermatol 2006
368
15

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
K A Papp, S Tyring, M Lahfa, J Prinz, C E M Griffiths, A M Nakanishi, R Zitnik, P C M van de Kerkhof, Linda Melvin. Br J Dermatol 2005
513
15

Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials.
L Guenther, C Han, P Szapary, B Schenkel, Y Poulin, M Bourcier, J P Ortonne, H L Sofen. J Eur Acad Dermatol Venereol 2011
42
35

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
G G Krueger, R G Langley, A Y Finlay, C E M Griffiths, J M Woolley, D Lalla, A Jahreis. Br J Dermatol 2005
105
14

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Alan Menter, Steven R Feldman, Gerald D Weinstein, Kim Papp, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Cynthia Arnold, Alice B Gottlieb. J Am Acad Dermatol 2007
339
14

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
Dennis A Revicki, Mary Kaye Willian, Alan Menter, Kenneth B Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Miriam Kimel, Martin Okun. J Dermatolog Treat 2007
72
18


Cytokines sing the blues: inflammation and the pathogenesis of depression.
Charles L Raison, Lucile Capuron, Andrew H Miller. Trends Immunol 2006
13

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
506
13


A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
K A Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, R G Langley, J Cather, A B Gottlieb,[...]. Br J Dermatol 2016
244
13

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
S R Feldman, K B Gordon, M Bala, R Evans, S Li, L T Dooley, C Guzzo, K Patel, A Menter, A B Gottlieb. Br J Dermatol 2005
97
12

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.
E Daudén, C E M Griffiths, J-P Ortonne, K Kragballe, C T Molta, D Robertson, R Pedersen, J Estojak, R Boggs. J Eur Acad Dermatol Venereol 2009
74
16

Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.
R Krishnan, D Cella, C Leonardi, K Papp, A B Gottlieb, M Dunn, C F Chiou, V Patel, A Jahreis. Br J Dermatol 2007
86
13

Global epidemiology of psoriasis: a systematic review of incidence and prevalence.
Rosa Parisi, Deborah P M Symmons, Christopher E M Griffiths, Darren M Ashcroft. J Invest Dermatol 2013
12

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
N Müller, M J Schwarz, S Dehning, A Douhe, A Cerovecki, B Goldstein-Müller, I Spellmann, G Hetzel, K Maino, N Kleindienst,[...]. Mol Psychiatry 2006
511
12

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
Seyed-Hesameddin Abbasi, Fahimeh Hosseini, Amirhossein Modabbernia, Mandana Ashrafi, Shahin Akhondzadeh. J Affect Disord 2012
185
12

Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression.
Andrew H Miller, Vladimir Maletic, Charles L Raison. Biol Psychiatry 2009
12


Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
P C M van de Kerkhof, S Segaert, M Lahfa, T A Luger, Z Karolyi, A Kaszuba, G Leigheb, F M Camacho, D Forsea, C Zang,[...]. Br J Dermatol 2008
127
11

Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
Kristian Reich, Brad Schenkel, Ning Zhao, Philippe Szapary, Matthias Augustin, Marc Bourcier, Lyn Guenther, Richard G Langley. J Dermatolog Treat 2011
30
36

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
Alice B Gottlieb, Robert Evans, Shu Li, Lisa T Dooley, Cynthia A Guzzo, Daniel Baker, Mohan Bala, Colleen W Marano, Alan Menter. J Am Acad Dermatol 2004
408
11

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
J-H Saurat, G Stingl, L Dubertret, K Papp, R G Langley, J-P Ortonne, K Unnebrink, M Kaul, A Camez. Br J Dermatol 2008
501
11

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
K A Papp, C E M Griffiths, K Gordon, M Lebwohl, P O Szapary, Y Wasfi, D Chan, M-C Hsu, V Ho, P D Ghislain,[...]. Br J Dermatol 2013
271
11

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.
Shahin Akhondzadeh, Sara Jafari, Firoozeh Raisi, Abbas Ali Nasehi, Aboulfazl Ghoreishi, Bahman Salehi, Soodeh Mohebbi-Rasa, Maedeh Raznahan, Abbas Kamalipour. Depress Anxiety 2009
238
11

Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study.
Michael E Benros, Berit L Waltoft, Merete Nordentoft, Søren D Ostergaard, William W Eaton, Jesper Krogh, Preben B Mortensen. JAMA Psychiatry 2013
267
11

The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis.
Jonas Hannestad, Nicole DellaGioia, Michael Bloch. Neuropsychopharmacology 2011
543
11

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
441
11

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
R Gniadecki, D Robertson, C T Molta, B Freundlich, R Pedersen, W Li, R Boggs, A S Zbrozek. J Eur Acad Dermatol Venereol 2012
45
24


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.